Gilead Sciences Inc.’s (GILD) remdesivir, its coronavirus drug candidate, is most “beneficial” for Covid-19 patients who require supplemental oxygen but don’t need mechanical ventilation, according to a study by the National Institute of Allergy and Infectious Diseases (NIAID).”Ultimately, the findings support remdesivir as the standard therapy for patients hospitalized with Covid-19 and requiring supplemental oxygen therapy,” the report said, citing preliminary results from the randomized, controlled trial, published in The New England Journal of Medicine.Over a 10-day course, patients received the antiviral remdesivir intravenously and a placebo. The report showed that patients who received remdesivir had a shorter time to …read more
Source:: Yahoo Finance
